What is Mind Medicine Inc Annual Net Profit?

Mind Medicine Inc Annual Net Profit fell 13.52% in the last year to $108.68 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is Mind Medicine Inc Price to Earning Ratio?

Mind Medicine Inc Price to Earning Ratio is -3.94, which is negative.

What is Mind Medicine Inc Stock Price?

Mind Medicine Inc Stock Price fell 34.56% and underperformed its sector by 41.92% in the past year.

What is Mind Medicine Inc Quarterly Net profit?

Mind Medicine Inc Quarterly Net profit fell 45.58% YoY to $34.74 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is Mind Medicine Inc Debt to Equity Ratio?

Mind Medicine Inc Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Mind Medicine Inc Return on Equity(ROE)?

Mind Medicine Inc Return on Equity(ROE) for the last financial year was -68.01%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Mind Medicine Inc Mutual Fund Holding?

Mind Medicine Inc Mutual Fund Holding decreased by 0.29% in the last quarter to 20.83.

What is Mind Medicine Inc Interest Coverage Ratio?

Mind Medicine Inc Interest Coverage Ratio is -46.6, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Mind Medicine Inc Institutional Holding?

Mind Medicine Inc Institutional Holding increased by 0.02% in the last quarter to 55.35.

How is the Mind Medicine Inc today?

The Mind Medicine Inc today is trading in the down by -1.56% at 5.68.

How has Mind Medicine Inc performed historically?

The Mind Medicine Inc is currently trading down -1.56% on an intraday basis in the past week the index rose 4.60%. The index has been down -20.67% in the past quarter and fell -34.56% in the past year. You can view this in the overview section.

Mind Medicine Inc XNAS: MNMD

Mind Medicine Inc Live Share Price Today, Share Analysis and Chart

Name: Mind Medicine Inc: Is Infosys Ltd. worth buying?
Item: Mind Medicine Inc
Rating: 1.18000
Author: Trendlyne DVM scores

Download real time

5.68 -0.09 (-1.56%)

45.59% Fall from 52W High

217.6K XNAS Volume

XNAS 21 Apr, 2025 11:12 AM (EDT)

Mind Medicine Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	428.1
PE TTM Negative PE TTM Unavailable in chosen country	-3.9
PEG TTM High in industry Unavailable in chosen country	0.3
Price to Book Below industry Median Unavailable in chosen country	1.8
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	55.4
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-45.6
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-13.5
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-20.5
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-68
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-50.9

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

7.5 / 100

Technically Neutral

39.7 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Mind Medicine Inc Stock Price Analysis

Day Price Range -1.6% 1 Day return Unavailable in chosen country	5.7 (LTP) 5.55.7 LowHigh
Week Price Range 4.6% 1 Week return Unavailable in chosen country	5.7 (LTP) 5.45.8 LowHigh
Month Price Range -14.6% 1 Month return Unavailable in chosen country	5.7 (LTP) 4.77 LowHigh
52 Week Price Range -34.6% 1 Year return Unavailable in chosen country	5.7 (LTP) 4.710.4 LowHigh

View full Share Price History

Mind Medicine Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Mind Medicine Inc Stock Analysis

Mind Medicine Inc stock analysis with key metrics, changes, and trends.

Mind Medicine Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$108.68 M	13.52%	negative	Annual Net Profit fell 13.52% in the last year to $108.68 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-3.94	-	negative	Price to Earning Ratio is -3.94, which is negative.
Stock Price	$5.68	-34.56%	negative	Stock Price fell 34.56% and underperformed its sector by 41.92% in the past year.
Quarterly Net profit	$34.74 M	45.58%	negative	Quarterly Net profit fell 45.58% YoY to $34.74 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.09	-	positive	Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-68.01 %	-68.01%	negative	Return on Equity(ROE) for the last financial year was -68.01%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	20.83 %	-0.29%	negative	Mutual Fund Holding decreased by 0.29% in the last quarter to 20.83.
Interest Coverage Ratio	-46.6	-	negative	Interest Coverage Ratio is -46.6, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	55.35 %	0.02%	positive	Institutional Holding increased by 0.02% in the last quarter to 55.35.

VIEW LESS

Loading data..

Mind Medicine Inc - Company Profile

What does Mind Medicine Inc do?

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine Inc Management structure

All Gross Remunerations are in USD

Dr. Miri Halperin Wernli, PhD

Executive President

2025

Gross Remuneration

2024

Gross Remuneration

Year

Mind Medicine Inc Live Share Price Today, Share Analysis and Chart

45.59% Fall from 52W High

Mind Medicine Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Mind Medicine Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Mind Medicine Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Mind Medicine Inc Stock Analysis

Mind Medicine Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 13.52% in the last year to $108.68 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -3.94, which is negative.

Stock Price fell 34.56% and underperformed its sector by 41.92% in the past year.

Quarterly Net profit fell 45.58% YoY to $34.74 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -68.01%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.29% in the last quarter to 20.83.

Interest Coverage Ratio is -46.6, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.02% in the last quarter to 55.35.

Mind Medicine Inc - Company Profile

What does Mind Medicine Inc do?

Mind Medicine Inc Management structure

Dr. Miri Halperin Wernli, PhD

Executive President

Mind Medicine Inc Board of directors

Mr. Andreas Krebs

Vice Chairman of the Board

Mr. David W. Gryska, M.B.A.

Independent Director

Ms. Carol A. Vallone

Chairman of the Board

Dr. Roger Crystal, M.D.

Independent Director

Dr. Suzanne L. Bruhn, PhD

Independent Director

Mr. Robert B. Barrow

Chief Executive Officer and Director

Mind Medicine Inc FAQ

How is Mind Medicine Inc today?

Mind Medicine Inc today is trading in the red, and is down by -1.56% at 5.68.

How has Mind Medicine Inc performed historically?

Mind Medicine Inc is currently trading down -1.56% on an intraday basis. In the past week the stock rose 4.60%. stock has been down -20.67% in the past quarter and fell -34.56% in the past year. You can view this in the overview section.